Anti-tumor activities of active ingredients in Compound Kushen Injection

Acta Pharmacologica Sinica

Volumn 36, Issue 6, 2015, Pages 676-679

  Wang, Wei ^a,b,c   You, Rong Li ^a,d   Qin, Wen Jie ^a   Hai, Li Na ^a   Fang, Ming Jing ^a   Huang, Guo Hua ^e   Kang, Rui Xia ^d   Li, Ming Hua ^b   Qiao, Yu Feng ^b   Li, Jian Wei ^b,f   Li, An Ping ^b  

^a Beijing Zhendong Guangming Pharmaceutical Institute   (China)

^b Shanxi Zhendong Pharmaceutical Co Ltd   (China)

^c ZHUHAI PEOPLE S HOSPITAL ZHUHAI HOSPITAL AFFILIATED WITH JINAN UNIVERSITY   (China)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f Chang Zhi Medical College   (China)

Author keywords

anti cancer drug; Compound Kushen Injection; matrine; oxymatrine; traditional Chinese medicine

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; KUSHEN; MATRINE; OXYMATRINE; UNCLASSIFIED DRUG; ALKALOID; HERBACEOUS AGENT; QUINOLIZINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHINESE MEDICINE; HUMAN; METASTASIS INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TUMOR INVASION; ANIMAL; INJECTION; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUGS, CHINESE HERBAL; HUMANS; INJECTIONS; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; QUINOLIZINES; TREATMENT OUTCOME;

EID: 84930655997     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.24     Document Type: Review

References (32)

1. Sun FG, Sun XY. "Sophora flavescens", in Shen Nong Ben Cao Jing. Scientific and Technical Documents Publishing House; 1999. p59.
2. Commission P. Pharmacopoeia of the People's Republic of China 2010 English Edition 2011: Chinese Pharmacopoeia Commission.
3. Bai MS, Wu ZP, Wang XC. Advances in research on adjuvant effects applying Traditional Chinese Medicine in cancer chemotherapy. J Modern Oncol 2010; 18: 597-601.
4. Li J, Lin HS, Hou W, Hua BJ. Idea and strategy of traditional Chinese medicine treatment for cancer. China Cancer 2010; 19: 735-8.
5. Yin SY, Wei WC, Jian FY, Yang NS. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med 2013; 2013: 302426.
6. Kitano H. Systems biology: a brief overview. Science 2002; 295: 1662-4.
7. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358: 502-11.
8. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet 2012; 81: 303-11.
9. Tian J, Wang WH, Gao HM, Wang ZM. Determination of matrine, sophoridine and oxymatrine in Compound Kushen Injection by HPLC. Zhongguo Zhong Yao Za Zhi 2007; 32: 222-4.
10. Qi L, Zhang J, Zhang Z. Determination of four alkaloids in Compound Kushen Injection by high performance liquid chromatography with ionic liquid as mobile phase additive. Se Pu 2013; 31: 249-53.
11. Sun M, Cao H, Sun L, Dong S, Bian Y, Han J, et al. Antitumor activities of kushen: literature review. Evid Based Complement Alternat Med 2012; 2012: 373219.
12. Shao H, Yang B, Hu R, Wang Y. Matrine effectively inhibits the proliferation of breast cancer cells through a mechanism related to the NF-κB signaling pathway. Oncol Lett 2013; 6: 517-20
13. Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang HH, et al. Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem 2012; 30: 631-41.
14. Dai ZJ, Gao J, Ji ZZ, Wang XJ, Ren HT, Liu XX, et al. Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3. J Ethnopharmacol 2009; 123: 91-6.
15. Luo C, Zhu Y, Jiang T, Lu X, Zhang W, Jing Q, et al. Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family. Toxicology 2007; 229: 245-52.
16. Zhang Z, Wang X, Wu W, Wang J, Wang Y, Xu X, et al. Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD). Phytother Res 2012; 26: 932-7.
17. Yan F, Liu Y, Wang W. Matrine inhibited the growth of rat osteosarcoma UMR-108 cells by inducing apoptosis in a mitochondrialcaspase-dependent pathway. Tumor Biol 2013; 34: 2135-40.
18. 2 cells by inducing apoptosis and autophagy. World J Gastroenterol 2010; 16: 4281-90.
19. Ma L, Wen S, Zhan Y, He Y, Liu X, Jiang J. Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med 2008; 74: 245-51.
20. Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S, et al. Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and akt inactivation. PLoS One 2012; 7: e46853.
21. Jiang H, Hou C, Zhang S, Xie H, Zhou W, Jin Q, et al. Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol 2007; 559: 98-108.
22. Li H, Xie S, Liu X, Wu H, Lin X, Gu J, et al. Matrine alters microRNA expression profiles in SGC-7901 human gastric cancer cells. Oncol Rep 2014; 32: 2118-26.
23. Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu W, et al. Oxymatrine diminishes the side population and inhibits the expression of betacatenin in MCF-7 breast cancer cells. Med Oncol 2011; 28 Suppl 1: S99-107.
24. Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang B, et al. Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. J Exp Clin Cancer Res 2011; 30: 66.
25. Song MQ, Zhu JS, Chen JL, Wang L, Da W, Zhu L, et al. Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells. World J Gastroenterol 2007; 13: 1788-93.
26. Song G, Luo Q, Qin J, Wang L, Shi Y, Sun C. Effects of oxymatrine on proliferation and apoptosis in human hepatoma cells. Colloids Surf B Biointerfaces 2006; 48: 1-5.
27. Xu W, Lin H, Zhang Y, Chen X, Hua B, Hou W. Compound Kushen Injection suppresses human breast cancer stem-like cells by downregulating the canonical Wnt/beta-catenin pathway. J Exp Clin Cancer Res 2011; 30: 103.
28. Zhou SK, Zhang RL, Xu YF, Bi TN. Antioxidant and immunity activities of Fufang Kushen Injection Liquid. Molecules 2012; 17: 6481-90.
29. Zhao Z, Fan H, Higgins T, Qi J, Haines D, Trivett A, et al. Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways. Cancer Lett 2014; 355: 232-41.
30. Shao Q. The recent effect of radiotherapy combined with compound kushen injection for esophageal cancer. Radiother Oncol 2011; 99: S372-3.
31. Sun Q, Ma W, Gao Y, Zheng W, Zhang B, Peng Y. Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma. Afr J Tradit Complement Altern Med 2012; 9: 178-88.
32. Bao Y, Yang L, Hua B, Hou W, Zhan S, Li W, et al. A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain. Support Care Cancer 2014; 22: 825-36.